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http://dx.doi.org/10.1016/j.jmii.2012Background: Antimicrobial resistance is a major determinant of Helicobacter pylori treatment
failures. We conducted a population-based survey to monitor changing antimicrobial suscepti-
bility of H. pylori isolates in Taiwan, with a focus on combinatorial effects of synergism and the
influence of acidity.
Methods: H. pylori isolates from endoscopic specimens taken from patients enrolled at two
medical centers were obtained between January 2008 and December 2009. Minimum inhibitory
concentrations (MICs) were determined by agar dilution and Etest methods. Agar media of
varying pH (pH 7.3, 6.0, or 5.0) were used to assess whether acidity influences the bactericidal
effects of the agents tested. Time-kill assays were used to assess for synergism between
different drug combinations.
Results: A total of 176 non-duplicate H. pylori isolates from endoscopic specimens were
tested. The following MIC90 (mg/L) (susceptible) results were obtained at neutral pH 7.3:
amoxicillin, 0.25 (100%); tetracycline, 0.5 (100%); metronidazole, 32 (67.6%); clarithromycin,
0.25 (90.3%); ciprofloxacin, 1 (92.0%); gemifloxacin, 0.5 (94.9%); levofloxacin, 1 (93.2%); and
moxifloxacin, 1 (91.5%). A decrease in pH from 6.0 to 5.0 significantly decreased the antimicro-
bial activity of levofloxacin and moxifloxacin against H. pylori. For clarithromycin-susceptibleInfectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, No. 7,
aiwan.
.tw (W.-H. Sheng).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Antimicrobial activity against H. pylori in Taiwan 73isolates, levofloxacin combined with clarithromycin provided both synergistic and bactericidal
effects. For clarithromycin-resistant isolates with amoxicillin hypersusceptibility (MIC
<0.01 mg/L), levofloxacin with amoxicillin or minocycline had at best additive effect but no
bactericidal effects.
Conclusion: Amoxicillin, tetracycline, clarithromycin, and fluoroquinolones, but not metroni-
dazole, showed good in vitro anti-H. pylori activity (>90% susceptible). Synergism was only
observed for clarithromycin-susceptible isolates. Acidity adversely influenced the antimicro-
bial activity of levofloxacin against H. pylori.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Helicobacter pylori is one of the most common causes of
chronic bacterial infections worldwide.1 Its prevalence is
significantly higher among patients with duodenal (>95%)
and gastric ulcers (80%) than in asymptomatic healthy
volunteers (50%),1e3 and its role in the pathogenesis of
peptic ulcer diseases, functional dyspepsia, and gastric
cancer is well recognized.4e7 Consequently, eradication of
H. pylori remains a primary goal for alleviating peptic ulcer
disease and preventing associated gastric malignancies.8,9
Over the past three decades, numerous regimens for H.
pylori eradication have been tested.10,11 Triple and
quadruple regimens containing at least two antibiotics
appear most successful and have been recommended by
the Maastricht IV guidelines for standard therapy.12 Among
the most popular first-line regimens are clarithromycin-
based triple therapy, containing a proton-pump inhibitor
(PPI) combined with amoxicillin (1 g) and clarithromycin
(500 mg) twice daily for 7 days, and a four-drug combina-
tion consisting of a PPI combined with bismuth (120 mg) and
tetracycline (500 mg) four times daily and metronidazole
(500 mg) three times daily. Understandably, H. pylori
strains resistant to clarithromycin, amoxicillin, metronida-
zole, and levofloxacin have become increasingly prevalent
worldwide, including Taiwan.13,14 However, antimicrobial
susceptibility patterns have not been uniformly predict-
able.15 Resistance rates reported vary from 10% to 90% for
metronidazole, from 0% to 45% for clarithromycin, from 0%
to 33% for amoxicillin, from 5% to 59% for tetracycline, and
from 6% to 21% for levofloxacin.13,16e18
Since antibiotic resistance is the major determinant of
treatment failure,19 there is an ongoing need to define
resistance rates locally and to monitor these changing
susceptibility patterns to guide optimal therapy. Hence, we
undertook a population-based survey of the antimicrobial
susceptibility of H. pylori isolates collected from northern
and southern regions in Taiwan.Materials and methods
Patients
Between January 2008 and December 2009, we enrolled
patients undergoing upper gastrointestinal endoscopy for
isolation of H. pylori from endoscopic specimens at the
National Taiwan University Hospital (NTUH) and at E-DaHospital in northern and southern Taiwan, respectively.
Only non-duplicate H. pylori isolates were studied. H.
pylori samples were recovered from antral biopsies from
patients positive for a Campylobacter-like-organisms test
(Pronto-Dry, Medical Instruments, Brignais, France).
Demographic characteristics including age, sex, underlying
systemic diseases, symptoms requiring endoscopic exami-
nation, and clinical diagnosis were recorded. To exclude
secondary resistance of the strains, patients who had taken
antimicrobial agents within 3 months prior to endoscopic
examination or had a history of previous antimicrobial
therapy to eradicate H. pylori infection were excluded.
This study was approved by the Ethics Committee of NTUH
(IRB-NTUH-REO No. 200702009). Informed consent was
obtained from all patients.
Biopsy specimens and culture for H. pylori
Gastric biopsy specimens were stored in cysteine freezing
medium at e80 C before processing in a sterile tissue
grinder with heat-inactivated fetal bovine serum. Samples
were inoculated onto blood agar (tryptic soy agar with 5%
sheep blood), onto chocolate agar, and onto Brucella agar
containing 10% horse blood, trimethoprim, vancomycin,
and polymyxin B. All cultures were incubated at 37 C under
microaerophilic conditions and high humidity (12% CO2, 98%
humidity) for up to 10 days. Positive cultures were usually
identified after 3e5 days of incubation. Isolates were
identified as H. pylori on the basis of positive catalase,
oxidase, and urease reactions; typical uniform, small,
translucent colonies; curved Gram-negative bacilli on
Gram-stained smears; susceptibility to cephalothin (30 mg);
and resistance to nalidixic acid (30 mg).
Antimicrobial susceptibility tests for H. pylori on
agar of different pH
Minimal inhibitory concentrations (MICs) were determined
by agar dilution methods according to the Clinical and
Laboratory Standards Institute (CLSI) as previously
described.20,21 In brief, H. pylori was inoculated onto
antibiotic-containing MuellereHinton agar supplemented
with 5% defibrinated sheep blood. The MIC of each antibi-
otic was determined after 72 h of incubation. H. pylori
ATCC 43504 was used as the quality control strain.
In addition, the susceptibility of the isolates was tested
using the Etest method (Epsilometer test; AB Biodisk, Solna,
Sweden) as recommended by the British Society for
74 A. Cheng et al.Antimicrobial Chemotherapy (BSAC) with two minor modi-
fications.22 In brief, colonies from a 2-days culture on
a blood agar plate were suspended in sterile distilled water
to an adjusted McFarland 3 standard. Brucella chocolate
agar with 7% sheep blood was used instead of Muel-
lereHinton agar with 5e10% horse blood. The 140-mm-
diameter agar plates were inoculated by confluent swab-
bing of the surface with the adjusted inoculum suspensions.
Five Etest strips were aseptically placed onto the dried
surface of each inoculated agar plate. The plates were
incubated at 37 C instead of 35 C under microaerophilic
conditions for 3 days. The MICs were read after 72 h of
incubation on the basis of the intersection of the elliptical
zone of complete growth inhibition with the MIC scale on
the Etest strip according to the manufacturer’s instruc-
tions.23 The following control strains were used: ATCC
43504, ATCC 43526, and ATCC 43579. Each strain was tested
at least twice using Etest strips from different batches.
Testing was performed using agar culture media at
different pH values (neutral pH 7.3  0.1, and acidic pH 6.0
and 5.0).
The breakpoints used to classify strains as susceptible or
resistant according to MIC are listed in Table 1. The
breakpoints for clarithromycin were interpreted according
to CLSI recommendations. The breakpoints for amoxicillin,
metronidazole, and tetracycline were interpreted accord-
ing to the BSAC recommendations (not published by CLSI).
Quinolones are not standardized by the CLSI nor BSAC, so
we used the recommendations of the Societe´ Franc¸aise de
Microbiologie, in accordance with other authors.23
Antimicrobial synergism of different
combinations of antibiotics
Time-kill curves for different levofloxacin-based combina-
tions were plotted to investigate for synergism against
H. pylori isolates. Time-kill analyses were performed for
two clarithromycin-susceptible and four clarithromycin-
resistant H. pylori isolates. Each H. pylori isolate was
subcultured twice on blood agar plates and a bacterial
suspension of 108 colony-forming units (CFU)/mL was
prepared based on a 1.0 McFarland standard. Aliquots of
MuellereHinton broth with 5% lysed horse blood were
inoculated with the bacterial suspension to yield a final
suspension of 5  105 CFU/mL. The antimicrobial agents
tested for synergism were added to yield concentrationsTable 1 Minimum inhibitory concentration for various antimic
pH 7.3
Antimicrobial agent Inhibitory concentration (mg/L)
MIC50 MIC90 MIC range
Amoxicillin 0.03 0.25 0.008e0.5
Tetracycline 0.125 0.5 0.008e1
Metronidazole 4 32 0.03e12
Clarithromycin 0.06 0.25 0.008e>1
Ciprofloxacin 0.5 1 0.016e>1
Gemifloxacin 0.125 0.5 0.008e8
Levofloxacin 0.5 1 0.03e>1
Moxifloxacin 0.5 1 0.008e>10.5 times their MIC. Control experiments without active
compounds were conducted simultaneously. The final
volume for each bacteriumedrug concentration was 10 mL
and samples were kept in a shaking water bath at 35 C. An
aliquot was taken from each sample at 0, 3, 6, and 24 h
after addition of the antimicrobial combination. Multiple
1:10 dilutions were made in saline and were subcultured
onto blood agar plates and incubated under 5% CO2 for
18e24 h. Studies were repeated three times on consecutive
days and time-kill data are presented as mean  standard
deviation. At each time interval, the log10 value of the
viable colony count was determined. The lower limit of
quantification in this model was 10 CFU/mL. Synergy of an
antimicrobial combination was defined as a 2 log10
decrease in CFU/mL compared with its more active
constituent. Bactericidal activity was defined as a minimum
3 log10 reduction in bacterial count at 24 h.
24
Results
A total of 176 H. pylori isolates from endoscopic specimens
were collected from 176 patients, 129 of whom were
enrolled at the NTUH site and 47 patients at the E-Da site.
MIC50 and MIC90 values for the eight antimicrobial agents
tested are shown in Table 1. Amoxicillin and tetracycline
showed good in vitro activity against the isolates, but the
MIC range for metronidazole was very wide. The MIC
distributions were lower for newer than for older quino-
lones, with gemifloxacin on the far left and ciprofloxacin on
the far right (Figs. 1 and 2).
Antimicrobial susceptibility test results according to
agar pH are shown in Table 2. When the acidity of the
environment was increased from pH 7.0 to pH 6.0, the MIC90
for ciprofloxacin increased significantly across breakpoints.
When the pH was further decreased from 6.0 to 5.0, the
MIC90 for levofloxacin increased significantly across break-
points, whereas smaller elevations in the MIC90 for amoxi-
cillin, clarithromycin, tetracycline, moxifloxacin and
gemifloxacin and in the MIC50 for metronidazole were
observed.
Six H. pylori isolates with varying clarithromycin MICs,
including two clarithromycin-susceptible isolates (HP-311,
HP-246) and four clarithromycin-resistant isolates (HP-109,
HP-103, HP-143, HP-82), were randomly selected for
in vitro antimicrobial synergy testing (Table 3). Drug
combinations of levofloxacin and clarithromycin,robial agents tested against 176 H. pylori isolates at neutral
Resistance (%) Breakpoint criteria (mg/L)
Susceptible Resistant
0.0 1 2
0.0 2 4
8 32.4 4 8
6 9.7 0.25 1
6 8.0 1 2
5.1 1 2
6 6.8 1 2
6 8.5 1 2
Figure 1. Minimum inhibitory concentration distributions for the 176 H. pylori isolates tested against amoxicillin, metronidazole,
and tetracycline.
Antimicrobial activity against H. pylori in Taiwan 75levofloxacin and amoxicillin, and levofloxacin and minocy-
cline were tested. Time-kill assays for isolates susceptible
to clarithromycin revealed bactericidal and synergistic
effects for clarithromycin combined with levofloxacin
(Fig. 3). However, for H. pylori isolates with clarithromycin
resistance, additive but not synergistic or bactericidal
effects were observed for levofloxacin þ amoxicillin or
levofloxacin þ minocycline combinations. The benefit of
adding a second drug to amoxicillin for clarithromycin-
resistant isolates was more pronounced when the amoxi-
cillin MIC for the isolates was <0.01 mg/L (Fig. 4).
Discussion
Our investigation revealed that amoxicillin, tetracycline,
clarithromycin, and fluoroquinolones still show good
in vitro anti-H. pylori activity in Taiwan. An increase in
acidity significantly reduced antimicrobial susceptibility to
fluoroquinolones. Synergism or an additive effect ofFigure 2. Minimum inhibitory concentration distributions for th
floxacin, levofloxacin, moxifloxacin, and gemifloxacin.levofloxacin combinations with clarithromycin, amoxicillin,
or minocycline was highly dependent on the susceptibility
of H. pylori isolates to clarithromycin. The present study
provides important information regarding the prevalence of
drug-resistant H. pylori in Taiwan.
We found that approximately one-third of pre-treatment
H. pylori isolates were resistant to metronidazole and
one-tenth to clarithromycin. While our updated resistance
rates to metronidazole show a rebound from the interim
trough reported for this region (from 25.4% to 32.4%),25
the rates for clarithromycin have remained stable over
the last decade.13 Thus, more frequent H. pylori eradi-
cation failures may be anticipated when metronidazole is
used in first-line regimens in areas where metronidazole
resistance is prevalent, such as Taiwan and Tunisia.11,20,26
For the increasing yet fluctuating patterns of antimicrobial
resistance of H. pylori isolates, susceptibility testing
(either phenotypic or genotypic) of H pylori isolates prior
to empirical treatment would be optimal in terms ofe 176 H. pylori isolates tested against clarithromycin, cipro-
Table 2 Antimicrobial susceptibility tests performed in acidic agar culture media (pH 5.0 and 6.0)
Antimicrobial agent Inhibitory concentration (mg/L)
pH 6.0 pH 5.0
MIC50 MIC90 MIC range MIC50 MIC90 MIC range
Amoxicillin 0.125 0.125 0.016e0.25 0.19 0.25 0.125e0.5
Tetracycline 0.09 0.125 0.03e0.25 0.19 0.5 0.06e0.5
Metronidazole 2 16 2e32 4 16 2e32
Clarithromycin 0.5 1 0.25e>16 0.5 1.5 0.25e>16
Ciprofloxacin 0.75 2 0.25e16 0.75 2 0.5e>16
Gemifloxacin 0.25 0.5 0.125e4 0.5 0.75 0.125e8
Levofloxacin 0.5 1 0.5e8 1.5 2 0.5e8
Moxifloxacin 1 2 0.5e8 4 6 0.5e16
76 A. Cheng et al.achieving higher eradication rates without fueling
resistance.12,14,20
However, since pretreatment antimicrobial suscepti-
bility testing is not widely available in Taiwan to guide
initial therapy, physicians should note that metronidazole
resistance has been consistently associated with female
sex.17,27 In addition, since metronidazole resistance rates
vary according to overall metronidazole consumption rates,
its future role in empiric H. pylori therapy will continue to
evolve depending on changing susceptibility rates.
Despite its lack of novelty, amoxicillin showed good
in vitro activity, indicating that amoxicillin should still be
the first choice for H. pylori eradication in Taiwan. Clari-
thromycin resistance rates of <15e20% indicate that the
empiric clarithromycin-based triple therapy proposed by
the Maastricht IV/Florence consensus remains applicable to
our population.12
In this study we also observed minimal in vitro resistance
to older shelved drugs such as tetracycline and to cipro-
floxacin. These drugs may potentially be used as salvage
therapy for patients for whom the above clarithromycin-
based standard first-line therapy fails.28 In agreement
with a previous report,29 we found that newer generation
fluoroquinolones such as gemifloxacin were superior to
other fluoroquinolones against clinical H. pylori isolates.
Whether gemifloxacin provides better clinical outcomes
than other fluoroquinolones through fewer iterative failures
warrants further studies.
The effect of pH changes on the activity of antimicrobial
agents, in particular for the newer quinolones, has not beenTable 3 Antimicrobial susceptibility of six H. pylori
strains randomly selected to represent the clarithromycin
susceptibility range
H. pylori strain Antimicrobial susceptibility (mg/L)
Amoxicillin Clarithromycin Levofloxacin
HP-311 0.006 0.006 0.5
HP-246 0.5 0.125 0.5
HS-109 0.06 >16 0.5
HS-103 0.016 >16 8
HS-143 0.008 >16 1
HS-82 0.008 >16 0.25well described for H. pylori.30e32 Our data demonstrate
that an increase in pH enhanced the bactericidal activity of
all antibacterial agents against H. pylori, albeit to varying
extents. However, the influence of pH on MIC breakpoints
appeared most marked for selected fluoroquinolones,
namely for ciprofloxacin and levofloxacin, wherein a cate-
gorical change from susceptible to resistant is observed
when the acidity levels increased from a pH 7.0 to 6.0 and
from pH 6.0 to pH 5.0, respectively. Changes in gastric
acidity can also affect the expression of bacterial target
sites and survival.33,34 Together, these effects observed
in vitro contribute to the potentiating in vivo effects
of concomitant acid suppression therapy for H. pylori
eradication. A lower pH did not appreciably alter the
bactericidal effects of metronidazole, as previously
described.30,31,34
In Taiwan, current eradication regimens available for H.
pylori include triple drug combinations comprising a proton
pump inhibitor and two antibiotics, amoxicillin plus metro-
nidazole, clarithromycin plus metronidazole, or clari-
thromycin plus amoxicillin, with eradication rates of 70%,
79%, and 89%, respectively.35 Although it may be possible to
explain these eradication rates by considering primary
resistance rates to individual agents alone, we used time-
kill assays to explore the potential for synergism between
various agents in levofloxacin-based combinations.
Previous studies have not reliably demonstrated in vitro
synergy between various combinations of amoxicillin,
clarithromycin, and metronidazole with a proton-pump
inhibitor for antibiotic-resistant strains of H. pylori.36,37
To the best of our knowledge, there are no reports in
the English literature that clarify the interactions of
levofloxacin with a second antibiotic, especially for
clarithromycin-resistant strains, for which levofloxacin
might play a role in salvage therapy. Our study demon-
strated that clarithromycin susceptibility predicted good
antimicrobial synergism for the combination of levofloxacin
(instead of amoxicillin) and clarithromycin. However, for H.
pylori isolates with clarithromycin MIC values >1 mg/L,
levofloxacin combined with either amoxicillin or minocy-
cline was neither synergistic nor bactericidal. This result
supports findings by Gotoh et al., who observed that when
a strain was resistant to one drug (especially clari-
thromycin) in a combination, no synergism was detected.37
Figure 3. Time-kill assays for clarithromycin (CLR)-susceptible H. pylori strains (A) HP-311 and (B) HP-246. There is good
antimicrobial synergism and bactericidal effects for levofloxacin (LEV) and CLR combinations against these two strains.
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effect for isolates with amoxicillin MIC values >0.01 mg/L.
Previous time-kill studies predicted synergism if an
isolate is sensitive to both antibiotics used in the combi-
nation.37 However the most interesting finding from our
time-kill assays was that given clarithromycin resistance,
despite dual sensitivity to amoxicillin and levofloxacin, this
combination was not synergistic. Amoxicillin rather than
levofloxacin MIC values predicted whether levofloxacin
combinations have an additive effect or not.
A levofloxacin-containing cocktail or sequential therapy
may replace standard triple therapy in areas with high
(>15e20%) clarithromycin resistance.12 However, for
clarithromycin-resistant isolates, we observed indifferent or
at best additive effects using levofloxacin-containing combi-
nations. Hence, concurrent levofloxacin-based therapy
would not be expected to be superior to sequential rescue
therapy. Our group confirmed this in a clinical trial ofsequential salvage therapy consisting of esomeprazole
40 mg and amoxicillin 1 g for the first 5 days, followed by
esomeprazole 40 mg, levofloxacin 250 mg, and metronida-
zole 500 mg for another 5 days (all given twice daily) in
patients for whom standard triple therapy failed. Eradica-
tion rates were >95% using this sequential levofloxacin-
containing regimen in the absence of metronidazole
resistance [26].
Our results suggest that both amoxicillin and clari-
thromycin remain pivotal in the therapy of H. pylori-
associated disease. The susceptibilities to these agents
define the synergism of levofloxacin-based antimicrobial
and PPI combinations. Hence, pre-salvage treatment
susceptibility testing for clarithromycin, amoxicillin, and
metronidazole to define resistance and/or multiple drug
resistance patterns of H. pylori isolates should be consid-
ered as a more advanced treatment approach at the indi-
vidual and population level.
Figure 4. Time-kill assays for clarithromycin (CLR)-resistant H. pylori strains HP-109, HP-103, HP-143, and HP-82. None of the
levofloxacin (LEV)-based combinations demonstrated a bactericidal effect for CLR-resistant isolates. No synergism was observed
for isolates, with amoxicillin (AMO) MICs >0.01 mg/L regardless of LEV susceptibility (3A, 3B). Pronounced additive effects existed
between LEV and AMO or minocycline (MIN) combinations for isolates, with AMO MICs <0.01 mg/L (3C, 3D).
78 A. Cheng et al.Our study supports the continued use of amoxicillin in
combination with clarithromycin as first-line therapy for
H. pylori in urban Taiwan. Quinolones should be reserved
as second-line therapy. Since all antimicrobial activities
were enhanced at higher pH values, the two other
prerequisites for effective treatment are adequate acid
suppression and good drug compliance. Although additive
effects were observed when levofloxacin was combined
with a second effective antibiotic, no in vitro synergism
existed to support concurrent sequential regimens to
eradicate clarithromycin-resistant H. pylori.
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